Explore 10,000+ laboratory markers, in plain English.

Blastocystis spp. (Protozoa) Biomarker in GI Effects Panel: Microscopic O&P vs. PCR Parasitology Microscopic O&P (Ova & Parasites) The GI Effects panel employs microscopic fecal specimen examination for ova and parasites (O&P), considered the gold standard for diagnosing many parasitic infections. In this methodology, Blastocystis spp. is identified based on its physical presence in the stool sample, often indicating an active or substantial colonization. Blastocystis resides primarily in the ileum and cecum, where it adheres to the outer mucus layer and thrives in an anaerobic environment, feeding on bacteria. Its presence has been linked to: - Increased microbial diversity and richness, potentially functioning as a commensal organism. - Indicators of dysbiosis in certain cases, where it may signify gut imbalance. PCR Parasitology - Protozoa The PCR methodology detects Blastocystis spp. through its genetic material, offering high sensitivity even at low levels of colonization. Unlike microscopic examination, PCR may identify subclinical or non-pathogenic strains, which might not correlate with significant microbial imbalance or symptoms. When only one method (PCR or O&P) detects Blastocystis, the clinical relevance is often weaker, as the level of colonization appears to influence its associations with symptoms or microbiota. Unique Insights from O&P vs. PCR The microscopic O&P method reflects direct observation, indicating higher colonization or active parasitism, whereas PCR may detect Blastocystis at subclinical levels. These differences highlight the importance of integrating both results for comprehensive interpretation. Blastocystis spp. Clinical Implications Associated Symptoms and Conditions: - Gastrointestinal: Nausea, loss of appetite, abdominal pain, diarrhea (acute/chronic), constipation, flatulence, anal itching. - Systemic: Fatigue, joint pain, urticaria (hives), and potential links to Irritable Bowel Syndrome (IBS). - Asymptomatic in many cases. Importance of Subtyping Blastocystis spp.: Subtypes are thought to influence symptoms and treatment response, though more research is needed to confirm their clinical significance. Understanding subtype variability may enhance personalized treatment strategies. Treatment Options Conventional Treatments: - Asymptomatic cases: No treatment is typically recommended. - Symptomatic cases: Options include metronidazole, TMP/SMX, iodoquinol, nitazoxanide, or emerging triple-antibiotic therapies. Natural Approaches: - Probiotics: Saccharomyces boulardii has shown favorable outcomes, especially in children. - Dietary Modifications: High-fiber, lactose-free diets may reduce symptoms. - Botanicals: Brucea javanica, Coptis chinensis, garlic (especially for subtype 1), and oregano oil demonstrate some efficacy in research studies. Challenges in Eradication: Blastocystis spp. can be difficult to eliminate entirely, particularly due to resistance in certain subtypes. Combining treatments and addressing gut health holistically may improve outcomes. Key Considerations - Epidemiology: Blastocystis is globally prevalent, often associated with fecal contamination of food or water. - Clinical Significance: Not all cases of Blastocystis colonization lead to symptoms, necessitating careful interpretation of test results in the clinical context. - Therapeutic Options: Integration of conventional and natural approaches, including antiparasitic therapies and probiotics, can be effective. Understanding the context in which Blastocystis is identified—whether through microscopic O&P or PCR—provides deeper insights into its role in gut health and potential symptoms.

Multiple sclerosis

Blautia hydrogenotrophica is a beneficial bacterial species within the Blautia genus, commonly found in the human gut microbiome.

What is the blood-brain barrier and why is it important? The blood-brain barrier (BBB) is a critical, protective structure in the human body. It functions as a highly selective filter between the bloodstream and the brain. Its main role is to protect the central nervous system (CNS) from potentially harmful substances—such as toxins, pathogens, and inflammatory molecules—while allowing essential nutrients and gases to pass through. The barrier is formed by tightly connected endothelial cells in the brain’s blood vessels, supported by astrocytes, pericytes, and the extracellular matrix. This structure ensures that the internal environment of the brain remains stable, which is essential for healthy cognitive function, memory, and neurological signaling. When the blood-brain barrier is compromised—a condition often called “leaky brain”—undesirable substances can cross into brain tissue. This may trigger neuroinflammation, autoimmunity, and neurodegeneration, contributing to conditions like multiple sclerosis (MS), brain fog, depression, chronic fatigue, cognitive decline, and even Alzheimer’s disease. What does this marker measure? The Blood-Brain Barrier Protein IgG + IgA marker assesses whether your immune system is producing antibodies (IgG and IgA) against specific structural proteins that make up the blood-brain barrier. IgG antibodies reflect systemic or long-term immune responses. IgA antibodies reflect mucosal or surface-level immune activity, often originating in barrier tissues such as the gut, lung, or brain lining. Elevated levels of these antibodies suggest that the immune system has been exposed to and is reacting against blood-brain barrier proteins, which typically should be hidden from immune surveillance. This is a strong indication of BBB disruption, either past or ongoing. What does an elevated result mean? An elevated Blood-Brain Barrier Protein IgG + IgA level suggests: Compromise or damage to the blood-brain barrier, allowing immune recognition of previously protected brain structures. Ongoing or previous immune activation against components of the BBB, pointing to chronic inflammation or autoimmune processes affecting the brain. A possible breach that may have been triggered by: Traumatic brain injury (even mild concussions) Chronic stress Infections (viral, bacterial, fungal) Systemic inflammation or autoimmunity (e.g., lupus, celiac disease, multiple sclerosis) Environmental exposures (e.g., heavy metals, mycotoxins) Chronic gut permeability (“leaky gut”) and cross-reactivity between gut and brain barriers Long-term use of medications such as NSAIDs or certain antibiotics Clinical relevance The presence of IgG + IgA antibodies to BBB proteins is a biomarker of immune dysregulation in the central nervous system (CNS) and may serve as an early warning sign of neurological disease—even before symptoms are severe or diagnosable. Conditions in which elevated BBB antibodies may be relevant include: Multiple sclerosis (MS) Parkinson’s disease Alzheimer’s disease Chronic inflammatory demyelinating polyneuropathy (CIDP) Cognitive decline or memory loss Mood disorders (depression, anxiety) Traumatic brain injury (TBI) Chronic fatigue syndrome Autism spectrum disorder Neuropsychiatric autoimmune conditions (e.g., PANS/PANDAS in children) What if the result is within range? A result that is within the normal reference range suggests that: The blood-brain barrier is currently intact, with no abnormal antibody production against its proteins. There is no significant immune activation or systemic breach involving the BBB at the time of testing. This is generally considered a healthy and stable finding. However, normal results should still be interpreted alongside symptoms, history, and other lab findings, particularly in individuals with neurological complaints or autoimmune disorders. Next steps if elevated If Blood-Brain Barrier Protein IgG + IgA is elevated, your provider may recommend: Additional testing for autoimmunity, infections, or systemic inflammation Functional brain assessments, such as neurocognitive testing or neuroimaging Anti-inflammatory support, including dietary interventions (e.g., gluten-free, anti-inflammatory diets), omega-3 fatty acids, and targeted antioxidants Gut-brain axis support, especially if gut permeability or microbiome imbalances are suspected Avoidance of environmental triggers such as mold, chemicals, or heavy metals Therapies to restore barrier integrity, including nutrients that support endothelial and astrocyte health (e.g., glutathione, curcumin, vitamin D, resveratrol) Summary The Blood-Brain Barrier Protein IgG + IgA marker on Cyrex’s Array 20 is a powerful tool for identifying whether your immune system is reacting against the protective lining of the brain. Elevated results suggest a breach in this critical barrier, allowing immune components to interact with—and potentially damage—neurological tissues. This marker provides early insight into neuroinflammation, autoimmunity, or environmental exposures that may be contributing to cognitive or neurological symptoms. Whether you're seeking answers for brain fog, fatigue, or more serious conditions, understanding BBB integrity is an important step in protecting your long-term brain health.

What is the Blood-Brain Barrier and Why Does It Matter? The blood-brain barrier (BBB) is a specialized, protective structure that separates the brain from the bloodstream. It acts as a biological shield—only allowing select molecules (like oxygen, glucose, and nutrients) to pass through while blocking toxins, pathogens, and inflammatory chemicals. This barrier helps keep the brain’s internal environment tightly regulated and protected from external threats. The BBB is made up of tightly connected endothelial cells, supported by glial cells (astrocytes) and pericytes. When the barrier is intact, it prevents the immune system from seeing or attacking the brain’s own tissues. When the barrier is damaged or becomes "leaky," immune cells and large molecules can enter the brain, potentially triggering inflammation, neurodegeneration, or autoimmune activity. What Does This Marker Measure? The Blood-Brain Barrier Protein IgM marker detects IgM-class antibodies against structural proteins of the blood-brain barrier. This test specifically measures the immune system’s early-stage response to damage or dysfunction in the BBB. IgM is the first antibody type produced in an immune response. It typically reflects acute or recent immune activation, often in response to new or ongoing tissue damage. In the context of the BBB, IgM antibodies suggest that the immune system has been recently exposed to normally hidden proteins from the brain’s protective lining—indicating a possible breach or compromise in the barrier. What Does an Elevated IgM Result Mean? An elevated Blood-Brain Barrier Protein IgM level usually indicates: Recent or acute damage to the blood-brain barrier, leading to leakage of structural proteins into circulation and immune exposure. New immune activity targeting the BBB, often in response to infections, head trauma, inflammation, or environmental exposures. An early warning sign that the brain’s immune privilege is breaking down—this can precede or coincide with neurological or cognitive symptoms. Potential triggers of elevated IgM to BBB proteins include: Viral or bacterial infections (systemic or neurotropic) Traumatic brain injury or concussion Recent exposure to neurotoxins (mold, heavy metals, solvents) Intestinal permeability (“leaky gut”) and systemic inflammation Acute emotional or physical stress Autoimmune activation Early-stage neurodegenerative processes (e.g., mild cognitive impairment) This marker is especially valuable in identifying early immune activation before more long-standing damage develops. It helps distinguish acute or reversible BBB dysfunction from more chronic or advanced barrier breakdown (which may show up as elevated IgG or IgA). Clinical Implications An elevated IgM response is a red flag for current or recent injury to the brain’s protective barrier. It may appear before the onset of overt neurological symptoms and is a valuable tool for early intervention. This marker is particularly important in individuals who: Experience recent head trauma, whiplash, or neurological infections Report sudden onset of cognitive issues, memory lapses, or brain fog Are at risk for autoimmunity or systemic inflammation Are exposed to environmental neurotoxins (e.g., mold, glyphosate, mercury) Have a personal or family history of neurodegenerative or neuropsychiatric conditions What If the Result Is Within Range? A normal Blood-Brain Barrier Protein IgM level suggests: No recent or active immune attack against BBB proteins The barrier is likely intact, with no major acute exposures or trauma There is no detectable early-stage immune response to barrier damage at the time of testing This result is considered favorable and is especially reassuring when paired with normal IgG and IgA levels on the same panel. However, results should always be interpreted in the context of symptoms and overall immune status. What To Do If IgM Is Elevated If your Blood-Brain Barrier Protein IgM is elevated, your provider may recommend: Identifying and removing triggers: infections, toxic exposures, food sensitivities, or systemic inflammation Further testing: inflammatory markers, neuroautoantibodies, or neuroimaging depending on symptoms Supporting BBB repair with nutrients and compounds shown to stabilize or rebuild the barrier: Omega-3 fatty acids (especially DHA) Antioxidants like glutathione and curcumin Vitamin D, resveratrol, and magnesium Stress-reduction and sleep optimization Addressing gut-brain axis integrity, since increased intestinal permeability can worsen BBB dysfunction through shared immune mechanisms Summary The Blood-Brain Barrier Protein IgM marker on Array 20 is a sensitive indicator of early immune activation against the brain’s protective barrier. Elevated levels suggest that the body has recently detected and responded to damage or disruption of the BBB. This can be a critical early warning sign of neurological risk, especially in the context of infections, toxic exposures, trauma, or systemic inflammation. Detecting BBB breakdown early provides a unique opportunity to intervene, support repair, and potentially prevent longer-term brain inflammation or neurodegenerative changes.

Keep a record of your blood donation history, including donation dates and types. Understand how blood donation may affect your hemoglobin and iron levels.

Kidney waste marker from protein breakdown; part of every CMP.

a physical barrier of endothelial cells and tight junctions

Blueberry IgG reactivity marker

BMI Categories: Underweight = <18.5 Normal weight = 18.5–24.9 Overweight = 25–29.9 Obesity = BMI of 30 or greater

Tracking body weight over time is crucial for maintaining and improving health for several reasons. Firstly, it allows for the early detection of unhealthy trends, such as rapid weight gain or loss, which can be indicators of underlying health issues like hormonal imbalances, metabolic disorders, or nutritional deficiencies. Regular monitoring helps in maintaining a healthy weight, a key factor in preventing chronic diseases such as diabetes, heart disease, and certain cancers. Additionally, it enables individuals to assess the effectiveness of their dietary and exercise regimes, guiding necessary adjustments for achieving personal health goals. This tracking also provides motivational feedback, as visible changes in weight can reinforce healthy lifestyle choices. Furthermore, it aids healthcare professionals in making informed decisions about a patient's health and in customizing treatment plans. In essence, regular weight tracking is a simple yet powerful tool for promoting long-term health and well-being.

Bone Fraction on Labcorp's Alkaline Phosphatase Isoenzyme Panel The Bone Fraction on Labcorp's Alkaline Phosphatase (ALP) Isoenzyme Panel represents the portion of alkaline phosphatase originating from bone tissue. Elevated levels of the bone fraction may indicate conditions such as Paget's disease, osteomalacia, or bone metastases, which involve increased bone turnover. This isoenzyme is specifically measured to differentiate the source of elevated ALP levels, allowing healthcare providers to pinpoint bone-related disorders. The ALP isoenzyme panel utilizes electrophoresis or other advanced techniques to separate and identify different ALP isoenzymes, providing valuable insights into bone health. By evaluating the bone fraction, clinicians can accurately diagnose bone diseases and guide appropriate treatment.

used to assess bone metabolism and turnover

causes whooping cough

Bordetella pertussis is the bacterium responsible for causing whooping cough, a highly contagious respiratory illness. The Bordetella pertussis toxin (PT) IgG antibody test is an immunoassay (IA) designed to detect the presence of IgG antibodies against the pertussis toxin. These antibodies are produced by the immune system in response to an infection with Bordetella pertussis or, in some cases, following vaccination. The presence of IgG antibodies to the pertussis toxin can indicate either a past infection with Bordetella pertussis or a response to a recent vaccination, as the pertussis vaccine (DTP or DTaP) contains inactivated components of the toxin. This marker is particularly useful for diagnosing recent or past infections, as well as for assessing immunity in individuals who may have been vaccinated or exposed to the bacteria. In general, high levels of IgG antibodies to the pertussis toxin suggest that a person has either been exposed to the bacterium or vaccinated, and may indicate immunity against future infections. However, a positive result alone cannot confirm whether the antibodies are a result of a current infection or past exposure, as the body may continue to produce IgG antibodies for years after the initial exposure. The Bordetella pertussis toxin (PT) IgG antibody test is commonly used in conjunction with other diagnostic tests, such as PCR (Polymerase Chain Reaction) or culture tests, to confirm a diagnosis of pertussis, particularly in individuals who present with symptoms resembling those of the disease but may not have the characteristic "whooping" cough. This test plays a crucial role in public health surveillance, especially in monitoring pertussis outbreaks and assessing vaccination coverage in populations. It also provides valuable insight for healthcare providers in diagnosing and managing whooping cough in individuals who may have had previous exposures or vaccinations.